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Mitogen-activated protein kinase kinase kinase 1, or MAP3K1, has been 
shown in a number of studies to be associated with luminal A subtypes of 
breast cancer.  However, in the absence of any functional studies, whether 
this association is more than causative remains to be seen.  I have 
knocked out MAP3K1 expression in both the non-tumorigenic MCF-10A cell 
line as well as the tumorigenic MCF-7 cell line in order to ascertain its 
role in breast cancer biology and development.  Further, a number of other 
genetic alterations were carried out, including estrogen receptor 
expression, PIK3CA activation, and MAP2K4 silencing.  MAP3K1 loss doesn’t 
seem to have any effect on growth, morphology, or sensitivity to selected 
drugs.  In the presence of the other modifications, though, there are some 
interesting changes in cell biology such as morphology and signaling of 
downstream proteins, such as Erk1/2, c-Jun, and ATF-2 that are affected 
only in the presence of MAP3K1 loss.  Taken as a whole, MAP3K1 loss alone 
may not be sufficient to induce carcinogenic changes, but in combination 
with other genetic changes may contribute to tumorigenicity.  
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INTRODUCTION 
Breast cancer is a common; with an estimated 234,190 new cases and 
40,730 deaths in America in 2015, it ranks as the most prevalent 
(excluding skin cancer) and second deadliest cancer in women (Siegel, 
2015).  Breast cancer is a heterogeneous disease that is typically 
separated into four subtypes: luminal A, luminal B, HER2 amplified, and 
basal-like.  Luminal A and B tumors both express the estrogen receptor and 
are therefore dependent upon estrogen for growth; luminal A differs from 
luminal B in having a lower expression of ki-67 and therefore a less 
proliferative phenotype (Inic, 2014).  Anti-estrogens, such as Tamoxifen, 
can be used to great effect to block the hormone-dependent growth of 
luminal breast tumors.  HER2-amplified tumors have an amplification or 
overexpression of the receptor tyrosine kinase ERBB2 gene.  While more 
aggressive than luminal tumors, the recent advent of the monoclonal 
antibody trastuzumab (known as Herceptin) and targeted therapies that take 
advantage of antibody development have greatly improved the outcomes of 
patients with this breast cancer subtype.  Basal-like breast cancers, also 
characterized as triple negative breast cancers, which do not express the 
estrogen receptor, progesterone receptor, or HER2 are difficult to treat 
and generally have the worst outcomes.  Although these subtypes are broad 
in definition, researchers have been seeking to more acutely define breast 
tumors based on a number of molecular characteristics in hopes that 
targeted therapies can be used for such tumors to a maximum effect. 
 Within the past five years, one avenue researchers have been taking 
in order to fine tune the breast cancer subtypes has been through large-
scale sequencing of tumors of the different subtypes.  This has yielded a 
number of genes that appear mutated in breast cancer that had previously 
not been identified including AKT2, CASP8, NCOR1, and MAP3K1 (Stephens, 
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2012).  As MAP3K1 has consistently arisen in such sequencing studies, and 
given its role as a kinase and the potential therapeutic options that 
could open, I decided to further investigate the role of MAP3K1 in breast 
cancer and the implications for treatment when it is lost. 
 Mitogen-activated protein (MAP) kinase kinase kinase 1, or MAP3K1, 
is a serine/threonine kinase that regulates MAP2K4 and JNK activation.  
MAP3K1 also has an E3 ligase domain that ubiquitylates c-Jun and ERK1/2.  
Serving as key node within the MAP kinase pathway, MAP3K1 has been 
associated with cell survival, migration, cell cycle regulation, and 
apoptotic regulation (Pham 2013).  Knockout studies in mice have revealed 
that although MAP3K1 is not essential to life, intact and fully 
functioning MAP3K1 is necessary for complete embryonic eyelid closure 
(Jin, 2012).  Further, although data available from The Cancer Genome 
Atlas Project (TCGA) suggest that with current treatment methods, patients 
with MAP3K1 loss do not appear to have a significantly better or worse 
prognosis compared to patients with normal expression of MAP3K1, there is 
not enough data to be conclusive (Cancer Genome Atlas, 2012).  This is the 
case in all subtypes of breast cancer as well as in estrogen receptor 
positive tumors, in which MAP3K1 mutations are most prevalent.  
 As stated above, recent large-scale sequencing studies have shown 
that MAP3K1 is mutated in a large proportion of breast cancers, 
specifically those in the luminal A subtype.  A study undertaken by The 
TCGA performed whole-exome sequencing on 510 breast tumors from 507 
patients to identify over 30,000 somatic mutations.  They found that 8% of 
tumors across all breast cancer subtypes had MAP3K1 mutations; when 
further characterized by subtype, this includes 13% of all luminal A 
tumors, 5% of luminal B tumors, 4% of HER2-amplified tumors, and none of 
the basal-like triple negative tumors (TCGA, 2012).  Further, they also 
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identified that 12% of luminal A tumors contain likely inactivating 
mutations in either MAP3K1 or MAP2K4, which are in the same branch of the 
map kinase pathway.  This is particular interesting as MAP3K1 directly 
activates MAP2K4. 
 Another study conducted by the Cancer Genome Project at the Wellcome 
Trust Sanger Institute similarly identified mutations in MAP3K1 as 
potentially new drivers of breast cancer.  They looked at the entire 
exomes of 100 breast tumors of which 79 were of the luminal, ER positive 
subtypes to identify 7,241 somatic point mutations (Stephens, 2012).  They 
found somatic mutations in MAP3K1 in 6% of all breast tumors but mostly in 
the luminal subtypes, most of which were truncating and many of which 
occurred in a biallelic fashion resulting in loss of function. 
 A third study did performed whole genome sequencing on 46 estrogen-
receptor positive breast tumors and whole exome sequencing on 31 in order 
to find out which genes are most associated with the different breast 
cancer subtypes as well as to discover the involvement in cancer of new 
genes.  They found that MAP3K1 mutation was most associated with luminal A 
breast tumors that were low-grade, and had low proliferation rates.  They 
further identified thirteen mutations in their samples in the MAP3K1 gene; 
most of these were nonsense and frameshift mutations that result in the 
predicted loss of function of that MAP3K1 allele.  They further noted a 
number of mutations in MAP2K4 (the substrate of MAP3K1) that tended to 
also be found in luminal A breast tumors but not in those that already had 
mutations in MAP3K1.  This mutual exclusivity of MAP3K1 and MAP2K4 
mutations suggests that the MAP kinase pathway specifically is related to 
luminal A breast cancer subtypes with MAP3K1 mutations contributing the 
bulk of this effect.  Building upon their initial findings, this group 
then investigated a validation set of 240 breast tumors and found 62 
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nonsynonymous mutations in either MAP3K1 (52 mutations in 39 tumors) or 
MAP2K4 (10 mutations) to makeup a total MAP3K1/MAP2K4 mutation frequency 
of 15.5%.  Of note, 13 of the tumors in this validation set had biallelic 
inactivation of MAP3K1 further indicating its role as a tumor suppressor 
(Ellis, 2012). 
 A number of studies have also pointed to a potential connection of 
MAP kinase signaling and the PI3K/AKT pathway (Laprise, 2004).  
Specifically, PI3K has been shown to downregulate MAP kinase signaling.  
Investigations into PI3K signaling have shown mechanistically that 
activated PIK3CA, a component of PI3K, leads to breast cancer.  Given that 
MAP3K1 loss is associated with breast cancer, it stands to reason that a 
potential mechanistic connection between activated PIK3CA and 
downregulated MAP3K1 may also exist in breast cancer.  This is further 
supported in the TCGA study which found PIK3CA missense mutations and 
MAP3K1 truncating mutations to coexist in a number of cancers (Cancer 
Genome Atlas, 2012)(Figure 1). 
 As MAP3K1 tends to be mutated in a large proportion of luminal 
breast cancers, I decided to further investigate the role of MAP3K1 in 
breast cancer and its implications for treatment.  While not estrogen-
receptor positive, MCF-10A cells are epithelially-derived as luminal 
subtype breast tumors are.  Specifically, though, estrogen-receptor 
positive breast cancer would be the best model for MAP3K1 loss as that 
seems to be the context of the majority of MAP3K1 mutations.  Although I 
took a number of avenues to investigate how MAP3K1 loss would affect 
breast cells, breast cancer cells, and treatment of such cells, for the 




METHODS AND RATIONALE  
Cell lines 
 From the literature, MAP3K1 appears to be a tumor suppressor gene 
that, in the context of breast cancer, mostly appears in estrogen-receptor 
positive tumors.  Although it is estrogen receptor negative, the non-
tumorigenic breast cell line, MCF-10A, was initially used to model MAP3K1 
loss.  MCF-10A is a widely used human breast epithelial cell line that is 
often used to model transformation.  As it is non-tumorigenic, breast 
cancer researchers use it to make genetic alterations to the cells and 
investigate their effects as regards classic tumor hallmarks.  Faster 
growth, abnormal morphology, or ability to invade a basement membrane and 
migrate may indicate that the genetic alterations that led to such 
phenotypes are involved in cancer.  MCF-7 is a tumorigenic, estrogen-
receptor positive breast cancer cell line that is derived from a luminal A 
tumor.  MCF-7, while having multiple copies of MAP3K1, expresses the gene 
normally (Figure 2).  Modeling MAP3K1 loss in the MCF-7 cell line may show 
changes in its tumorigenicity or modulate its response to therapies.   
MAP3K1 loss in MCF-10A cell line 
 MAP3K1 was targeted for deletion in MCF-10A cells by an adeno-
associated-virus based method that selectively inactivated its two alleles 
(Figure 3).  The targeting plasmid for the first allele was designed with 
homology arms flanking the second exon of MAP3K1 with a 1 kilobase long 
region missing between the two homology arms.  The homology arms directed 
the insertion of cre-lox sites that flanked an IRES-driven neomycin 
cassette which allowed for selection based on targeting.  Following 
homologous recombination and cre-mediated recombination, the one kilobase 
long region between the two homology arms was excised resulting deletion 
of exon 2 and subsequent inactivation of that allele.  The targeting 
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plasmid for the second allele similarly targeted exon 2, but in a 
different manner as using the same targeting vector for different alleles 
can result in retargeting of the first allele.  The homology arms were 
designed to target the region deleted by the first targeting construct, 
with the IRES-neo cassette integrating within the second exon.  Following 
homologous recombination and cre-mediated recombination, the loxP scar 
fell within the second exon and resulted in a frameshift with stop codons 
in all reading frames.  
The two targeting plasmids for the 2 MAP3K1 alleles were transformed 
into competent E. coli, purified via maxipreps, and sequenced to verify 
the plasmids.  These were then transfected into HEK293T cells along with 
the associated plasmids coding for adeno-associated viral packaging with 
FuGENE 6 transfection reagent.  Plasmids and the transfection reagent were 
diluted in serum-free, reduced growth medium, mixed, and added to HEK293T 
cells in T75 culture flasks.  After 3 days incubation, cells were 
harvested, spun down, and subjected to freeze-thaws in order to liberate 
adeno-associated virus particles.  The resulting mixture was then filtered 
to separate the virus particles from the cellular debris.  The day prior 
to infecting MCF-10A cells with the virus that targeted the first MAP3K1 
allele, cells were seeded in T75 culture flasks to achieve 50% confluency 
in growth arresting medium.  On the day of infection, medium was removed, 
10mL of virus was added, and cells were allowed to incubate for 24 hours.  
After 24 hours, 10mL fresh culture medium was added to the T75 culture 
flasks and cells were again allowed to incubate for another 24 hours, at 
which point the medium was removed and replaced with fresh medium with 
G418 at 120 ug/mL for 1 week with medium replaced after 3 days.  Clonal, 
single-allele MAP3K1 knockout MCF-10A cells were isolated through single-
cell dilution after PCR screening for targeted integration of the knockout 
construct on pools of cell colonies.  Following PCR verification of clonal 
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lines in which the targeting vector had correctly inserted, Cre 
recombinase was added to incubating cells for one day to remove the 
vector.  This process was repeated to knockout the second allele of MAP3K1 
in these cells.  Immunoblotting was used to confirm the presence or 
absence of fully functional MAP3K1 protein. 
MAP3K1 loss in MCF-7 cell line 
 Targeting MAP3K1 in MCF-7 cells proved to be more difficult than in 
MCF-10A cells.  For one, the tri-/tetra-ploid genome of MCF-7 necessitated 
multiple rounds targeting.  Also, targeting efficientcy was reduced in 
those cells for unknown reasons.  As such adeno-associated virus methods 
to target MAP3K1 in MCF-7 cells were ineffective, resulting in incomplete 
disruption of MAP3K1.  Thus, I took an approach that utilized the 
clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 
technology.  The CRISPR/Cas9 expression plasmid, LentiCRISPR, containing a 
puromycin resistance gene for selection as well as a promotor-driven 
cloning site were ordered from Addgene with short guide RNA (sgRNA) 
strands designed according to the tools provided by the Zhang lab at MIT 
(Hsu, 2013).  4 short guide RNAs (sgRNA) specific to MAP3K1 were cloned 
cloned into the CRISPR/Cas9 expression plasmid.  The four different 
plasmids each targeting a different area of MAP3K1 were amplified in E. 
coli, purified through maxipreps, and transfected in HEK293T cells along 
with packaging and envelope plasmids using FuGENE 6 transfection reagent 
for lentiviral packaging.  The day before transfection, HEK293T cells were 
seeded in 6-well culture plates such that they would reach 70% confluency 
the day of transfection.  Just prior to transfection, the CRISPR/Cas9-
sgRNA plasmids as well as both the packaging and envelope plasmids were 
diluted in serum-free, reduced growth medium and mixed with separately 
diluted transfection reagent before being added to HEK293T cells in 
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antibiotic-free medium.  Lentivirus particles were harvested two days 
later for infection of MCF-7 cells.  The four cell cultures then underwent 
selection with puromycin for three days and single-cell dilution in order 
to isolate independent, clonally-derived colonies.  Twenty-five verified 
clonally-derived colonies were screened via Western blotting to confirm 
the absence of functional MAP3K1 protein.   
Estrogen Receptor Expression in MCF-10A MAP3K1 knockout cell lines 
 While MCF-10A cell lines are a useful cell culture model to study 
genetic changes that may be important in the development of cancer and 
serve as a model for transformation, a potential drawback for the purposes 
of studying MAP3K1 is its lack of estrogen receptor alpha expression.  As 
had been previously shown, MAP3K1 is primarily lost in luminal breast 
cancers in which the estrogen receptor is expressed.  So while MAP3K1 loss 
in MCF-10A cells may elucidate the role of MAP3K1 in certain contexts, it 
may not correctly capture the role of MAP3K1 in its proper biological 
context.  As such, expressing the estrogen receptor in the MCF-10A derived 
cell lines would better model MAP3K1 loss as it actually happens in breast 
cancer.   
 The Park lab has been an innovator in modeling estrogen dependent 
growth in MCF-10A cells.  They have created an expression plasmid that, 
when transfected into estrogen-receptor negative cells, will express the 
estrogen receptor alpha, allow for stable selection, and convert the 
biology of the cells into one dependent upon estrogen for growth.  The 
resulting MCF-10A cells that have been transfected with this plasmid and 
are newly dependent upon estrogen for growth have been termed ERIN 
(estrogen receptor in non-tumorigenic) cells.  They found that these cells 
express the estrogen receptor alpha and are growth stimulated by 17-beta-
estradiol in the absence of epidermal growth factor (Abukhdeir, 2006).  
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Further, growth of these cells in the presence of 17-beta-estradiol is 
blocked by selective estrogen receptor modulators, such as tamoxifen. 
 Using this same estrogen receptor expression plasmid, I transfected 
my MCF-10A MAP3K1 knockout cells, the MCF-10A MAP3K1 heterozygous cells, 
and MCF-10A wild type cells in order to make them growth-dependent on 
estrogen using the FuGENE 6 transfection reagent.  Cells were plated the 
day before transfection in 6-well culture plated such that they would 
around 70% confluent on the day of transfection.  Just prior to 
transfection, transfection reagent was incubated with serum-free, reduced 
growth medium and mixed with diluted plasmids containing the estrogen 
receptor alpha expression plasmid in serum-free, reduced growth medium.  
This mixture was then added to the above-mentioned cells in antibiotic-
free culture medium and allowed to incubate or 48 hours after which they 
were selected with G418 at 120 ug/ml.  Estrogen receptor alpha expression 
was assayed via Western blotting. 
PIK3CA activation in MCF-10A MAP3K1 knockout cell lines 
 Additionally, some previous studies have shown potential crosstalk 
between the MAP kinase and PI3K-Akt pathway in breast cancer.  This is 
further supported by the fact that many breast cancers have been found to 
have mutations in both MAP3K1 and PIK3CA (Figure 1).  As such, double 
mutant cell lines were created in MCF-10A cells in which MAP3K1 was both 
knocked out as described above and an activating mutation in PIK3CA was 
knocked in.  The Park lab has done extensive work characterizing MCF-10A 
cells in which PIK3CA has been activated via a mutation in either exons 9 
or 20 (Gustin, 2009).  Either an E545K mutation in exon 9 or H1074R 
mutation in exon 20 confer constitutive activation to PIK3CA.  They found 
that MCF-10A cells in which PIK3CA had been activated exhibited 
transformed phenotypes, most notably growth factor-independent growth.  
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Further, the Park lab found that activation of PIK3CA led to downstream 
phosphorylation of MEK/ERK signaling, a pathway which could cross-talk 
with MAP3K1.  Thus it is reasonable to hypothesize that there may be 
synergistic effects in tumorigenesis in losing MAP3K1 and activating 
PIK3CA.   
 Using the same constructs that the Park lab used in their paper, I 
set about activating PIK3CA through both the exon 9 and 20 mutations in 
both wild-type MCF-10A cells as well as two MCF-10A MAP3K1 knockout cell 
line.  Both the E545K mutation in exon 9 and H1074R mutation in exon 20 
constructs were transformed into competent E. coli, purified via 
maxipreps, and sequenced to verify the plasmids.  These were then 
transfected into HEK293T cells along with the associated plasmids coding 
for adeno-associated viral processing with FuGENE 6 transfection reagent.  
Plasmids and the transfection reagent were diluted in serum-free, reduced 
growth medium, mixed, and added to HEK293T cells in T75 culture flasks.  
After 3 days incubation, cells were harvested, spun down, and subjected to 
freeze-thaws in order to liberate adeno-associated virus particles.  The 
resulting mixture was then filtered to separate the virus particles from 
the cellular debris.  The day prior to infecting MCF-10A cells and the 
derived MAP3K1 knockout MCF-10A cells with this virus, cells were seeded 
in T75 culture flasks to achieve 50% confluency in growth arresting 
medium.  On the day of infection, medium was removed, 10mL of virus was 
added, and cells were allowed to incubate for 24 hours.  After 24 hours, 
10mL fresh culture medium was added to the T75 culture flasks and cells 
were again allowed to incubate for another 24 hours, at which point the 
medium was removed and replaced with fresh medium with G418 at 120 ug/mL 
for 1 week with medium replaced after 3 days.  After this point, stable, 
clonally derived PIK3CA activating cells were isolated through single-cell 
dilution after PCR screening for homologous integration of the targeting 
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construct and verified by sequencing and growth in the presence and 
absence of epithelial growth factor. 
MAP2K4 silencing in MCF-7 cell line 
 Given how closely within the MAP kinase network MAP3K1 and MAP2K4 
are, and that mutations in either appear to be mutually exclusive and 
inactivating, I further set out to silence MAP2K4 expression in the MCF-7 
cell line.  The purpose of this was dual in nature: to initially see 
whether inactivating this node of the pathway would lessen the tumor 
phenotype of the cell lines and as a follow up, see if the resulting 
phenotype was similar to that seen when MAP3K1 expression was suppressed 
through CRISPR targeting.  Expression constructs containing short hairpin 
RNA (shRNA) specific to MAP2K4 were transfected into HEK293T cells using 
the FuGENE 6 transfection reagent alongside packaging and envelope 
plasmids for lentivirus packaging.  Cells were plated the day before 
transfection in 6-well culture plates such that they would be around 70% 
confluent on the day of transfection.  Just prior to transfection, 
transfection reagent was incubated with serum-free, reduced growth medium 
and mixed with diluted plasmids containing different shRNA’s with the 
associated lentivirus plasmids in serum-free, reduced growth medium before 
being added to HEK293T cells in antibiotic-free medium.  Lentivirus with 
each shRNA were harvested two days later and used to infect MCF-7 cells, 
after which they were incubated for 48 hours and assayed for MAP2K4 
expression. 
Phenotypic Assays 
 I carried out a number of assays to look into typical cancer-related 
phenotypes in order to investigate the effects of the above genomic 
modifications.  Growth assays were carried out according to conditions 
called for by the specific cell lines being investigated.  In the most 
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basic of cases, cells are to be seeded in either 6-well or 24-well culture 
plates at a low enough density to allow for growth by the end of the 
assay.  If the effects of drugs are to be investigated, the following day 
medium is removed and replaced with drug containing medium.  Cells are 
counted using a ViCell cell counter and normalized to a control (no 
genetic modification, no treatment, etc.).   
 Matrigel morphogenesis assays were carried out in order to 
investigate the effects of the above genetic modifications on the 
resulting cell line morphology in a simulated extracellular matrix.  While 
the normal, non-tumorigenic MCF-10A cell line develops into well-formed 
acini, transformed lines tend to form unique structures such as cellular 
extensions, interconnected lobes, and large cellular masses.  Matrigel 
morphogenesis assays were setup in 8-chamber culture slides.  Thawed 
Matrigel is initially coated onto the bottom of the slides and allowed to 
set.  Harvested cell lines are then suspended in Matrigel and seeded into 
each well of the chamber slide at a density of 1,000 cells/well.  Culture 
medium is then layered on top.  The slides are allowed to incubate for up 
to 3 weeks to allow for enough growth with the top layer of medium changed 
every 5 days. 
 A common method of visually viewing cell density is through staining 
with crystal violet.  Crystal violet is a cellular stain that will be 
taken up only by viable cells.  An added benefit to this technique is that 
crystal violet also fixes the cells, allowing for a visual comparison 
years into the future.  A 0.005% crystal violet solution is created by 
dissolving 0.5 grams of crystal violet in 25mL methanol and 75mL water.  
Medium is removed from cells and the crystal violet solution is added in a 
volume sufficient to just cover the cells.  The cells are incubated with 
the solution at room temperature for 30 minutes, after which point cells 
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are washed with DPBS to remove excess stain and allow visualization.  The 
resulting stained and fixed cells can be visually compared to others 
stained similarly to view differences in growth in different media as well 
as put into solution to allow for spectrophotometric comparisons. 
 Western blotting was used to investigate downstream effects of the 
genetic editing and drug studies.  For this, cells were seeded between 
250,000 and 500,000 cells in a 6-well culture plate and allow for growth 
for a specified time point, often for 24 to 48 hours.  Cells were cultured 
overnight in an experimentally relevant medium (with or without drug or 
growth factors) and lysates made the next day.  To collect whole cell 
lysates, media would be aspirated from the wells, rinsed with DBPS, and a 
sufficient mixture of 10% 2-mercaptoethaol/2X Laemmli sample buffer 
solution added to cover the cells.  Cells would then be scraped into a 
collection tube and boiled at 100 degrees Celsius for 10 minutes.  Total 
protein concentration would be quantified via the Pierce 660nm protein 
assay reagent in order to normalize the total protein load in the gel.  
Lysates were run on 4-12% Bis-Tris precast gels for sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis.  The proteins were transferred 
to Invitrolon PVDF, 0.45 µm pore size membranes after which they were 
blocked with a 5% milk/0.5% Tween 20/Tris-buffered saline solution.  
Blocked membranes were probed for a protein of interest through incubation 
at 4 degrees Celsius overnight in a solution of antibody diluted in 5% 
milk/0.5% Tween 20/Tris-buffered saline.  After rinsing the membrane, 
diluted secondary antibody specific to the primary antibody was incubated 
at room temperature for one hour in a 5% milk/0.5% Tween 20/Tris-buffered 
saline solution.  After rinsing, the membrane was briefly incubated in 
Perkin Elmer enhanced chemiluminescence western blotting substrate and 
visualized through exposure to film and subsequently developed.  
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Densitometric calculations were derived from ImageJ software and 
normalized by comparison to housekeeping protein expression levels. 
  
RESULTS AND DISCUSSION 
Creation of MAP3K1 knockout cell lines and other cell culture models 
MAP3K1 loss in MCF-10A cell line 
In all, 4 MAP3K1 knockout cell lines were successfully derived from 
MCF-10A wild-type cells (Figure 4).  Two independent clonal cell lines 
were derived from the wild-type MCF-10A cells in which one allele had been 
inactivated through the first targeting vector, called 13-B1 and 13-A2.  
From each of these, two more independent cell lines were clonally derived 
in which both alleles had been inactivated: 13-B1 yielded 5C95 and 6H92 
while 13-A2 yielded 5D95 and 6D91.  Additionally, two cell lines were 
derived from 13-B1 which had undergone the targeting and neomycin 
selection process but had non-homologous integration of the targeting 
construct, called 5C3 and 6H3.  5C3 and 6H3 had thus undergone the same 
procedures as the MAP3K1 knockout cell lines but retained one active 
allele; as such they can be used as controls for the MAP3K1 knockout cell 
lines as well as used to investigate the effect of MAP3K1 
haploinsufficiency compared to losing all copies of MAP3K1.  
Immunoblotting confirms that full length MAP3K1 is absent from the four 
MAP3K1 knockout cell lines derived from MCF-10A, 5C95, 6H92, 5D95, and 
6D91 (Figure 5).  The two single allele knockout cell lines, 5C3 and 6H3, 
retain full-length MAP3K1, although perhaps not to the extent that wild-
type MCF-10A cells do.   
The initial classic tumor phenotype I wanted to investigate in these 
derived cell lines was their growth kinetics (Figure 6).  Specifically, I 
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wanted to know whether MAP3K1 loss in this model induced growth factor 
independence, one of the hallmarks of tumorigenicity.  MCF-10A cells 
normally require epidermal growth factor (EGF) at a concentration of 20 
ng/mL but can grow slowly in 1% of that.  Growth is arrested in the 
absence of EGF.  In the absence of EGF, none of the derived cell lines 
showed any growth alone or in comparison to wild-type MCF-10A cells (data 
not shown).  This is regardless of how many days cells were allowed to 
grow or the initial seeding density.  In low EGF conditions of 0.2 ng/m 
(representative experiment shown in Figure 6), no cell line outperformed 
the others in terms of growth consistently.  Allowing growth to occur for 
eight days in this low EGF condition did not show any appreciably 
different growth kinetics.  At physiological EGF levels of 20 ng/mL, the 
MCF-10A derived MAP3K1 knockout, single-allele knockout, and wild-type 
MCF-10A cells consistently grew at similar rates.  These experiments 
demonstrate that MAP3K1 loss does not have any effect on the growth 
kinetics in the MCF-10A non-tumorigenic breast cell line. 
Similar to looking into the growth kinetics in culture, I wanted to 
know what the growth would be like in a three-dimensional culture model.  
Specifically, a Matrigel extracellular matrix culture was used to mimic 
the biological microenvironment of the tumor to see the morphology my MCF-
10A derived MAP3K1 cell lines would take.  In comparison to wild-type MCF-
10A cells, neither the two single-allele MAP3K1 knockout cell lines nor 
the four complete MAP3K1 knockout cell lines demonstrated any 
morphological differences compared to their wild-type MCF-10A counterparts 
(data not shown).  This was true regardless of whether they were cultured 
in physiologic levels of EGF (20 ng/mL) or low levels of EGF (0.2 ng/mL), 
or regardless of how long they were allowed to stay in culture.  MAP3K1 
loss, then, had no effect on the morphology of the MCF-10A non-tumorigenic 
breast cell line in Matrigel. 
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The effects of commonly used chemotherapeutic agents on the derived 
MCF-10A MAP3K1 knockout cell lines has important clinical implications.  
Should MAP3K1 loss sensitize the MCF-10A derived cell line, it may be an 
indication that women with such mutations would benefit from a given 
treatment.  I looked primarily into two chemotherapeutics: nocodazole and 
paclitaxel.  Nocodazole is a drug that interferes with microtubule 
polymerization; prolonged exposure to this and at high enough 
concentrations causes cell death due to growth arrest during mitosis.  
Paclitaxel also has its effects on microtubules; however, it prevents 
their degradation and eventually leads to cell death from their 
accumulation.  Paclitaxel is widely used clinically to treat breast 
cancer, whereas nocodazole is not a clinical drug. In other settings, 
MAP3K1 has been shown to be required for apoptosis induced by microtubule 
disruption (Johnson, 1999).  Figure 7 shows the growth of the different 
derived cell lines when exposed to the two above drugs.  Blue lines 
represent MCF-10A wild-type cells; the green lines represent the average 
of the 2 MCF-10A derived single-allele knockout cell lines 5C3 and 6H3; 
the red lines represent the average of the average of 4 MCF-10A derived, 
MAP3K1 knockout cell lines 5D95, 6H92, 6D91, and 5C95 with each cell line 
treated in triplicate.  Regardless of whether the cell lines were treated 
with nocodazole (Figure 7a) or Paclitaxel (Figure 7b), cell lines did not 
show an appreciable difference in growth indicating that MAP3K1 does not 
sensitize the MCF-10A non-tumorigenic breast cell line to either of these 
agents.   
MAP3K1 loss in MCF-10A cells did, however, have some effect on 
downstream protein signaling through the MAP kinase pathway that may have 
potential relevance for tumor behavior, specifically in the context of 
nocodazole treatment (Figure 8).  2 MCF-10A derived MAP3K1 knockout cell 
lines (6D91 and 5C95), 1 MCF-10A derived single-allele MAP3K1 knockout 
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cell line (5C3) and wild-type MCF-10A cells were treated with nocodozole 
and a DMSO vehicle control at 45 nM.  Cell lysates were collected at three 
time points: 1 hour, 8 hours, and 24 hours and immunoblotted for phospho-
c-Jun as well as the loading control marker GAPDH.  Phospho-c-Jun 
induction as a result of nocodazole treatment may be decreased in the 
MAP3K1 knockout cell lines compared to their wild-type and single-allele 
knockout controls. 
MAP3K1 loss in MCF-7 
 Of the twenty-five screened MCF-7 colonies transfected with the 
CRISPR-MAP3K1-KO plasmids, at least two single-cell derived clones from 
each sgRNA targeting construct had no expression of functional MAP3K1 
protein as assayed via western blotting.  Initial growth assays suggest 
that there was no significant difference in growth between any of the 4 
MAP3K1 knockout clones when compared to either an empty vector control or 
parental MCF-7 cells (data not shown). 
Estrogen Receptor Expression in MCF-10A MAP3K1 knockout cell lines 
 Of the MCF-10A derived MAP3K1 knockout cell lines I had been working 
with, I was able to induce estrogen receptor expression in four clones 
across the three main categories (Figure 9a).  Those in which estrogen 
receptor expression was induced include two parental MCF-10A cell lines, 
two heterozygous, single-allele knockout cell lines (of the 5C3 lineage), 
and three from the two-allele knockout cell lines (one of the 6H92 lineage 
and two of the 6D91 lineage).  Perhaps owing to their clonal nature, 
estrogen receptor expression was highly variable across the different 
derived lines and even within clones having the same parental cell line 
(Figure 9b).  
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 Wild-type MCF-10A cells normally require growth factors for growth.  
This is altered with the expression of the estrogen receptor, which allows 
the cells to grow dependent on estrogen instead.  Figure 10 shows a 
selection of estrogen receptor expressing cell lines (boxed in green) as 
well as those that underwent transfection of the estrogen receptor 
expression plasmid but did not show any appreciable expression levels 
(boxed in red) which have been stained with crystal violet after 17 days 
in culture.  In the absence of estrogen, no cell line exhibited any 
growth.  For those that show positive estrogen receptor expression (green 
boxes), growth is appreciably better in 17-beta-estradiol than in the 
ethanol vehicle control.  The growth seen in the estrogen receptor 
expressing cell lines is neutralized in the presence of the selective 
estrogen receptor modifiers tamoxifen and faslodex.  There does not appear 
to be any differential effect of 17-beta-estradiol on these cells with 
respect to MAP3K1 knockout status.  This suggests that any growth 
differential is due to factors other than MAP3K1 status. 
 The most significant difference regarding MAP3K1 loss in estrogen 
receptor expressing cells has to do with signaling downstream of MAP3K1 
(figure 11).  In the absence of epithelial growth factor, MAP3K1 knockout 
cells do not exhibit Erk1/2 activation whereas the parental MCF-10A cell 
lines that express estrogen receptor maintain the ability to activate 
Erk1/2.  Considering the role of the extracellular signal-regulated 
kinases, Erk1/2, in carcinogenesis, this finding warrants further 
investigation. 
PIK3CA activation in MCF-10A MAP3K1 knockout cell lines 
 A number of double mutant cell lines were derived in which MAP3K1 
had been knocked out and PIK3CA had been activated (Figure 12a).  PIK3CA 
had been activated both through the exon 9 and exon 20 mutations with most 
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phenotypic workup focused on the exon 9 mutation.  In the absence of 
growth factors, only those cell lines with activated PIK3CA (exon 9) 
exhibit growth.  However, MAP3K1 knockout status does not appear to affect 
this growth appreciably, as shown in the similar cell densities of the 
crystal-violet stained wells (Figure 12b).  As such, growth differences in 
these cell lines are most likely either related to their clonal nature or 
due to PIK3CA activation solely.   
There does, though, appear to be a difference in these double mutant 
cell lines’ ability to form acini in Matrigel (Figure 13).  The acini 
formed by the double mutant cells in which MAP3K1 was knocked out and 
PIK3CA activated have a much more abnormal morphology compared to either 
mutation alone.  This suggests the two mutations cooperate or synergize to 
alone cause aberrant morphology. 
 There were some interesting findings concerning downstream signaling 
proteins, though (Figure 14).  MAP3K1 loss in MCF-10A cells appears to be 
associated with increased ATF-2 (activating transcription factor 2) 
activation, decreased p38 (a mitogen-activated protein kinase) activation, 
and increased c-Jun activation.  Such findings may explain the tumorigenic 
qualities of MAP3K1 loss and deserve further research. 
MAP2K4 silencing in MCF-7 cell line 
 A number of clones were derived from MCF-7 cells that exhibited 
markedly reduced expression of MAP2K4.  Further workup of these cell lines 






 While there may be some effect of MAP3K1 loss in the development of 
breast cancer, I was not able to show definitively how or why that may be.  
The high prevalence of women with breast cancer having MAP3K1 loss is not 
likely due to it being a passenger mutation in the carcinogenesis process.  
This is based on previous genome-wide breast cancer studies consistently 
finding an association with disease as well as its mutual exclusivity with 
MAP2K4 which is not common in other cancer types.  More likely is that 
MAP3K1 may exert its effects in ways not investigated or yet to be 
identified.  For one, the models of MAP3K1 loss discussed above do not 
model all aspects of tumor biology.  The tumor microenvironment, tumor-
stroma interactions, and other factors associated with systems biology 
were not able to be investigated in such cell culture models.  Further, it 
may be that MAP3K1 is and its loss are important in the context of the 
breast, a more complex a organ than is able to be modeled accurately in 
cell culture.  MAP3K1 and its loss may also be significant in allowing for 
an ideal environment for tumorigenesis.  The assays employed above were 
used to elucidate the role MAP3K1 in tumorigenicity, but would miss its 
role in tumorigenesis.  The multiple changes in signaling pathways as a 
result of MAP3K1 loss, however, do demonstrate that further investigation 






Figure 1. Reproduction of Figure 1 from TCGA 2012 article showing class of 
mutations in highly mutated genes in breast cancer separated by subtype.  
This graphic shows significantly mutated genes within breast cancer 
subtypes (225 luminal A tumors, 126 luminal B tumors, 57 HER2-enriched 
tumors, 93 basal-like tumors).  Note that MAP3K1 mutations mainly manifest 
as a truncation mutation as opposed to a missense mutation.  This would 
likely result in inactive protein.  MAP3K1 mutations occur in 8% of all 
breast cancers but are enriched in Luminal A subtypes in which they occur 
at a rate of 13%.  In MAP3K1 and MAP2K4, proteins which occupy two 
contiguous steps in the MAP kinase pathway, mutations appear to be 
mutually exclusive, occurring in one or the other.  Further, a significant 
percentage of MAP3K1 mutations occur in luminal A tumors in which there is 
also a PIK3CA mutations (The Cancer Genome Atlas, 2012).  This figure is 
reproduced under the Creative Commons Attribution-Non-Commercial-Share 







Figure 2.  Comparison of the MCF-10A and MCF-7 cell line karyotypes.   
MCF-10A cells (top) are a non-tumorigenic, epithelial derived, mostly 
diploid cell line.  With the exception of a few transformations, the 
t(3;9) which confers immortality for one, MCF-10A is a mostly diploid cell 
line.  MCF-7, in contrast is a tri/tetra-ploid, estrogen receptor 
positive, growth factor independent breast cancer cell line.  (Cowell, 




























Figure 3. MAP3K1 targeting strategy in MCF-10A.  MCF-10A cells have 2 
alleles of MAP3K1; two targeting vectors were designed to each allele.  
The first allele was inactivated through the deletion of exon 2 while the 
second allele was inactivated through the interruption and subsequent 
























+/-	-/-	 -/-	 -/-	 -/-	
Figure 4.  MCF-10A MAP3K1 knockout cell lines.  The following are 
clonally-derived, independently isolated cell lines from MCF-10A in which 
either a single allele or both alleles of MAP3K1 has been inactivated.  
The green member on top with “+/+” is MCF-10A wild-type cell line from 
which all the following members were derived.  The yellow members on the 
second tier with “+/-“ are cell lines in which one allele has been 
inactivated via the first allele targeting vector.  The orange members 
with “+/-“ on the bottom tier were derived from the 13-B1 cell line and 
similarly have one allele inactivated.  However, these cell lines have 
also undergone targeting via the second allele targeting vector but 
underwent nonspecific integration of the targeting vector.  The red 
members with “-/-“ on the bottom tier were derived from either single 
allele inactivated cell lines and have both of their MAP3K1 alleles 









Figure 5.  Verification of MCF-10A MAP3K1 knockout cell lines by western 
blotting.  The knockout cell lines derived from MCF-10A cells have no 
full-length MAP3K1 protein.  The single-allele inactivation cell lines 






































































Figure 12.  PIK3CA activation in MCF-10A MAP3K1 knockout cell lines.  
Knockin of the activating PIK3CA hotspot mutations in exons 9 and 20 were 
verified through sequencing and growth patterns without growth factors.  2 
of the MCF-10A MAP3K1 knockout cells lines, 6H91 and 6D91, underwent 
targeted activation of PIK3CA.  2 clones from each of these cell lines 
each had PIK3CA activated through either the exon 9 or exon 20 mutation.  
Additionally MCF-10A wild-type cells underwent PIK3CA activation via 
mutation of both exons 9 and 20. 
a. Shown here is a representative G>A mutation in exon 9 of PIK3CA 
in wild-type MCF-10A cells.  The first panel is a chromatogram of 
wild-type MCF-10A cells showing a homozygous G at this location.  
The middle panel shows a chromatogram of a previously created and 
verified PIK3CA knock-in activating mutation in exon 9 in which 
one allele underwent a G>A mutation.  The last panel shows a 
chromatogram from one of my MCF-10A MAP3K1 knockout cell lines in 
which PIK3CA has been mutated from G>A in one allele similar to 





b. Representative crystal violet stained plate in which two of the 
MCF-10A MAP3K1 knockout cell lines (6H92 and 6D91) with activated 
PIK3CA (exon 9) as well as MAP3K1 knockout cell lines in which 
underwent targeting of PIK3CA but did not exhibit PIK3CA 
activation (labeled RI), MCF-10A wild-type cells, 6D91 & 6H92 
MAP3K1 knockout cell lines without activated PIK3CA, and MCF-10A 
with activated PIK3CA (exon 9) (labeled 512).  In the absence of 
growth factors, only those cell lines with activated PIK3CA (exon 
9) exhibit growth.  MAP3K1 knockout status does not appear to 












Figure 14. Downstream MAP3K1 signaling in either wild-type MCF-10A 
parental cells (left, green), MAP3K1 knockout cells (red), PIK3CA 
activated cells (purple), or double mutant cell lines in which both MAP3K1 
has been knocked out and PIK3CA activated (right, blue).  MAP3K1 loss in 
MCF-10A cells appears to be associated with increased ATF-2 (activating 
transcription factor 2) activation, decreased p38 (a mitogen-activated 
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as differential growth rates and chemotherapeutic susceptibility 
• Followed up my investigation with mutations of other genes in the map 
kinase pathway in other cell lines 
• Standardized a number of protocols pertaining to the assays performed 
in this newly started lab 
• Helped train undergraduate and summer students  




















Masters Research Scientist 
The University of Michigan School of Public Health Epidemiology Program 
2009-2011 
• Managed a project exploring the effect of the androgen receptor 
polyglutamine tract on the development of male breast cancer in North 
African populations 
• Designed study from the beginning including inclusion and exclusion 
criteria of cases and controls, established contacts in Egyptian and 
Moroccan hospitals where male breast cancer is especially common, and 
traveled to Egypt to procure viable control tissue 
• Developed and standardized a technique using amplified fragment length 
polymorphisms labeled with a fluorescent dye to precisely determine 
gene and receptor length in study subjects 
• Discovered that longer androgen receptors are associated with the 
development of male breast cancer 
• Published two first-author papers about breast cancer as well as 
assisted on various other projects that resulted in secondary 
authorships 
• Involved in recruiting and training students while in the cancer 




Undergraduate Research Technician 
The University of Michigan, Department of Human Genetics 
2006-2008 
• Genotyped and tended to transgenic mice colonies to determine androgen 
receptor length categories to determine association with female breast 
cancer 




Student Researcher  
The William Beaumont Hospital Department of Oncology, Royal Oak, MI 
2005-2007 
• Gathered information on breast cancer patients to input into databases 
• Created databases to organize to multiple relevant data points for each 
patient/project 
• Helped physicians write and prepare abstracts, manuscripts, and 
lectures 
• Assisted and observed radiation oncologists in all aspects of their job 
• Organized office procedures to ensure an efficient work environment 

















Johns Hopkins Center for Talented Youth 
2015 
• Taught gifted high school students the subject of genetics in a 
classroom setting 
• Designed lesson plans, classroom activities, quizzes/tests, and 
laboratory projects 
• Monitored student progress via assessment methods and one-on-one 
interaction and tailored lessons to ensure each student obtained the 
appropriate information 
• Supervised laboratory activities, instructed students on laboratory 
procedure and experimental technique, and helped students understand 
the processes involved 
• Worked closely with a teacher’s assistant to ensure proper classroom 
management 
• Partook in parent-teacher conferences to provide feedback to students 
and their families regarding their progress, constructive criticism, 




• Awarded second place in the poster competition among graduate students 
at The Maryland Genetics, Epidemiology, and Medicine Training Program 
Genetics Research Day 
 
 
TECHNICAL SKILLS SUMMARY 
Molecular Biology 
Gene cloning and vector design, gene expression assays (Western blotting, 
RT-PCT), PCR, qPCR, Sanger sequencing with the 3730xl DNA Analyzer 
Cell Culture 
Mammalian cell culture using cancer and normal cell lines, growth assays, 
drug sensitivity assays, morphology assays, gene targeting 
Computer Skills 




2014-present  Genetics Society of America 




INVITED PRESENTATIONS AND ABSTRACTS 
• Invited to talk and present at the International Cancer Education 
Conference in Cairo, Egypt; October 2010 
• Invited to talk and present at the American Association for Cancer 
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